BIOGENETIC SCIENCES, INC. RESPONDS TO INQUIRIES
New York, November 28, 2001 American Biogenetic
Sciences, Inc. (ABS) (NASDAQ:MABA) issued a press
release on Monday morning, November 26. The Nasdaq
Stock Market contacted the company and asked the company
to provide certain additional factual information
with respect to the matters described in the press
release. Pending receipt of that information, at 10:21
a.m. on Monday morning, The Nasdaq Stock Market halted
trading in the companys stock.
is actively working to provide The Nasdaq Stock Market
with the requested information and resolve any issues
as expeditiously as possible, but is unable at this
time to predict exactly when these issues may be resolved
and trading resumed.
Biogenetic Sciences, Inc., is based in Copiague, NY,
and researches and develops diagnostic tests for cardiopulmonary
conditions and infectious diseases, as well as for
new treatments for neurological disorders, including
epilepsy, migraine, mania, and Alzheimers disease.
As an innovative developer of biogenetic technologies
and compounds, ABS to date has been issued over 75
patents, both US and foreign, and there are over 100
in this release that are not strictly historical are
forward-looking statements within the
meaning of the Private Securities Litigation Reform
Act of 1995 and should be considered as subject to
various risks and uncertainties that could cause actual
results to differ materially from those anticipated.
For further details and a discussion of these risks
and uncertainties, see ABS Securities and Exchange
Commission filings including its annual report or
more information, please contact:
For a complete analysis of the ABS pipeline
go to: /research.html.